Suppr超能文献

加工位点在HLA - A2.1限制性、T细胞反应性肿瘤抗原表位和病毒表位的产生过程中有所不同。

Processing sites are different in the generation of HLA-A2.1-restricted, T cell reactive tumor antigen epitopes and viral epitopes.

作者信息

Yang X F, Mirkovic D, Zhang S, Zhang Q E, Yan Y, Xiong Z, Yang F, Chen I H, Li L, Wang H

机构信息

Department of Pharmacology, Temple University School of Medicine, Philadelphia, USA.

出版信息

Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):853-70. doi: 10.1177/039463200601900415.

Abstract

In order to improve the processing efficiency of T cell tumor antigen epitopes, this bioinformatic study compares proteolytic sites in the generation of 47 experimentally identified HLA-A2.1-restricted immunodominant tumor antigen epitopes to those of 52 documented HLA-A2.1-restricted immunodominant viral antigen epitopes. Our results show that the amino acid frequencies in the C-terminal cleavage sites of the tumor antigen epitopes, as well as several positions within the 10 amino acid (aa) flanking regions, are significantly different from those of the viral antigen epitopes. In the 9 amino acid epitope region, frequencies differed somewhat in the secondary-anchored amino acid residues on E3 (the third aa of the epitope), E4, E6, E7 and E8; however, frequencies in the primary-anchored positions, on E2 and E9, for binding in the HLA-A2.1 groove, remained almost identical. The most frequently occurring amino acid pairs in both N-terminal and C-terminal cleavage sites in the generation of tumor antigen epitopes were different from those of the viral antigen epitopes. Our findings demonstrate for the first time that these two groups of epitopes may be cleaved by distinct sets of proteasomes and peptidases or similar enzymes with lower efficiencies for tumor epitopes. In the future, in order to more effectively generate tumor antigen epitopes, targeted activation of the immunoproteasomes and peptidases that mediate the cleavage of viral epitopes could be achieved, thus enhancing our potential for antigen-specific tumor immunotherapy.

摘要

为提高T细胞肿瘤抗原表位的处理效率,这项生物信息学研究将47个经实验鉴定的HLA - A2.1限制性免疫显性肿瘤抗原表位生成过程中的蛋白水解位点与52个已记录的HLA - A2.1限制性免疫显性病毒抗原表位的蛋白水解位点进行了比较。我们的结果表明,肿瘤抗原表位C末端切割位点的氨基酸频率,以及10个氨基酸侧翼区域内的几个位置,与病毒抗原表位的氨基酸频率有显著差异。在9个氨基酸的表位区域,E3(表位的第三个氨基酸)、E4,、E6、E7和E8上的二级锚定氨基酸残基频率略有不同;然而,在HLA - A2.1凹槽中结合的E2和E9上的一级锚定位点的频率几乎保持相同。肿瘤抗原表位生成过程中N末端和C末端切割位点最常出现的氨基酸对与病毒抗原表位的不同。我们的研究结果首次证明,这两组表位可能由不同的蛋白酶体和肽酶或对肿瘤表位效率较低的类似酶切割。未来,为了更有效地生成肿瘤抗原表位,可以实现对介导病毒表位切割的免疫蛋白酶体和肽酶的靶向激活,从而增强我们进行抗原特异性肿瘤免疫治疗的潜力。

相似文献

3
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.针对前列腺酸性磷酸酶的 HLA-A2 限制性 T 细胞表位。
Cancer Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6. Epub 2010 Feb 6.

引用本文的文献

2
Vascular Endothelial Cells and Innate Immunity.血管内皮细胞与先天免疫
Arterioscler Thromb Vasc Biol. 2020 Jun;40(6):e138-e152. doi: 10.1161/ATVBAHA.120.314330. Epub 2020 May 27.

本文引用的文献

1
Vaccines for tumour prevention.用于肿瘤预防的疫苗。
Nat Rev Cancer. 2006 Mar;6(3):204-16. doi: 10.1038/nrc1815.
3
Processing and presentation of tumor antigens and vaccination strategies.肿瘤抗原的处理与呈递及疫苗接种策略
Curr Opin Immunol. 2006 Feb;18(1):98-104. doi: 10.1016/j.coi.2005.11.013. Epub 2005 Dec 15.
8
Induction and regulation of IFNs during viral infections.病毒感染期间干扰素的诱导与调节。
J Interferon Cytokine Res. 2004 Aug;24(8):439-54. doi: 10.1089/1079990041689665.
9
A listing of human tumor antigens recognized by T cells: March 2004 update.T细胞识别的人类肿瘤抗原列表:2004年3月更新
Cancer Immunol Immunother. 2005 Mar;54(3):187-207. doi: 10.1007/s00262-004-0560-6. Epub 2004 Aug 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验